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Abstract
Background. Atrial septal defect (ASD) and patent foramen ovale (PFO) are specific types of atrial septal 
communications (ASC).
Objectives. We aimed to assess quality of life (QoL) in patients before and after percutaneous closure of ASC 
and determine the factors influencing QoL in this group of patients.
Material and methods. We performed a clinical assessment and conducted an SF-36 questionnaire, 
electrocardiography and echocardiography studies in patients before and 6 months after percutaneous 
ASC closure.
Results. Patients with ASD (n = 56) had a lower SF-36 total score than those with PFO (n = 73), before 
and after percutaneous ASC occlusion (both p < 0.001). After the procedure, the improvement of SF-36 
total score in patients with ASD or atrial fibrillation was greater (p < 0.001 and p = 0.005, respectively). 
We observed correlations between improvement of QoL and baseline supraventricular extrasystolic beats 
(rs = 0.28; p = 0.002), but not ventricular extrasystolic beats (rs = 0.03; p = 0.76). Quality of life improvement 
was predicted in patients with ASD by higher baseline tricuspid annular plane systolic excursion (TAPSE) 
and right ventricular longitudinal dimension R2 = 0.38; p < 0.001. However, in patients with PFO, this was 
predicted by TAPSE, lack of arterial hypertension and usage of angiotensin-converting enzyme inhibitors, 
R2 = 0.30; p < 0.001.
Conclusions. Patients with ASD have lower QoL than those with PFO before and after percutaneous ASC 
occlusion. Six months after the procedure, the improvement of QoL in patients with ASD was higher than 
in those with PFO. The change in QoL self-assessed by patients after the procedure was associated with 
episodes of arrhythmia and was predicted with echocardiographic and clinical parameters.
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Introduction
Atrial septal communications (ASC) include ostium 
secundum atrial septal defect (ASD) and patent foramen 
ovale (PFO). The ASD is one of the most common con-
genital heart defects, while PFO is an anatomical variant. 
Those with ASD and PFO are considered as 2 different 
patient populations. The PFO is the most prevalent ASC 
and is diagnosed in about 26% (17–35%) of the population. 
A right-to-left shunt through PFO usually occurs during 
a temporary or permanent increase in right atrial pres-
sure. On the other hand, PFO with concomitant valvular 
regurgitation and/or stenosis may be associated with left-
to-right shunt. The PFO may lead to paradoxical embo-
lism, usually in circulation related to the central nervous 
system.1–3 The ASD comprises about 10% of all congenital 
heart defects diagnosed after birth.4–8 According to Euro-
pean Society of Cardiology guidelines, ASD with a hemo-
dynamically significant shunt (signs of right ventricular 
volume overload) and pulmonary vascular resistance <5 
Wood units should be closed. Moreover, closure of ASD 
and PFO should be considered in cases of previous para-
doxical systemic embolism.1,4
The importance of a quality of  life (QoL) assessment 
in patients undergoing various types of medical interven-
tions became apparent in the 1970s. With the advancement 
of medicine, therapeutic goals are not only set to remove 
the disease, which in many cases is not possible, but also 
to improve patient’s functioning in society, fulfillment 
of social roles and restoration of well-being.9–12
The aim of the study was to assess QoL in patients before 
and after percutaneous closure of ASC (ASD and PFO) and 
to determine the factors influencing QoL in this group 
of patients.
Material and methods
Patients
The methodology of the study has been previously de-
scribed in detail.13 Briefly, we included consecutive patients 
with ASD or PFO.
Inclusion criteria:
1) Presence of ASD or PFO planned for percutaneous 
closure.
2) Consent to undergo transthoracic echocardiography 
(TTE), transesophageal echocardiography (TEE), 24-hour 
Holter electrocardiogram (ECG) monitoring and percuta-
neous ASC closure, and to perform a clinical assessment 
including the SF-36 questionnaire, before and 6 months 
after the procedure.
Exclusion criteria:
1) Chronic atrial fibrillation (AF).
2) Patients after cardiac surgery, AF ablation or cardio-
vascular implantable electronic device placement.
3) The presence of significant valvular heart disease 
and/or other congenital cardiovascular defects and/or 
cardiomyopathy.
4) Left ventricular ejection fraction (LVEF) below 50% 
or dementia.
5) The presence of a significant leak around the  im-
planted septal occluder.
6) Sub-optimal imaging on echocardiography and poorly 
visible P-waves in ECG (non-echogenicity and poor ECG 
recording quality).
7) Incomplete SF-36 questionnaire.
We excluded patients with chronic AF and poorly visible 
P-waves because P-wave dispersion analysis was performed 
as a part of our study.13 From our study, we excluded 3 pa-
tients with chronic AF, 1 patient who did not complete 
the SF-36 questionnaire and 3 patients who did not re-
turn it. Furthermore, 1 patient was excluded due to a sig-
nificant leak around the implanted occluder.
Clinical history assessment and physical examination 
(including assessment of cardiovascular complaints and 
comorbidities) were performed before percutaneous clo-
sure of the ASD and PFO and 6 months after the procedure.
TTE, TEE and 24-hour  
Holter ECG monitoring
Transthoracic and transesophageal echocardiography 
studies were performed according to recommendations 
from international guidelines.13–19 using the Toshiba Power 
Vision system (Toshiba, Tokyo, Japan) and an ultrasound 
probe with a frequency from 2.5 MHz to 3.5 MHz. M-mode 
imaging, 2-dimensional (2D) imaging, pulse-wave Doppler, 
continuous wave Doppler, and color flow Doppler imag-
ing were used. Two-dimensional imaging was used to as-
sess the location and size of the ASC from standard views: 
parasternal cross-sectional view at the level of large vessels, 
apical 4-chamber, apical 5-chamber, and subcostal views. 
The morphology of the atrial septum was assessed during 
TEE in the bicaval view and high longitudinal view.16,17 Basic 
parameters of cardiac chamber quantification and valvular 
functions were assessed. Moreover, right ventricular pres-
sure and pulmonary to systemic blood flow ratio (Qp/Qs) 
were calculated. Assessment of the Holter ECG monitoring 
results was performed as previously described.13
Quality of life assessment
Assessment of QoL was based on a self-assessment of pa-
tients using a 36-item SF-36 questionnaire. The SF-36 ques-
tionnaire used in our study was composed of 11 points 
including 36 questions, which consisted of 8 subscales for 
the assessment of: SF1 – physical functioning (PF); SF2 
– limitations due to physical health, role-physical (RP); 
SF3 – social functioning (SF); SF4 – bodily pain (BP); SF5 
– mental health (MH); SF6 – role limitations due to emo-
tional problems, role-emotional (RE); SF7 – vitality (VT); 
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SF8 – general health (GH). In the final assessment, QoL in-
dex was calculated (SF-36 total score). In the interpretation 
of results, higher scores in the self-assessment of patients 
indicated better QoL.9–12
Written consent was given by all patients to perform 
studies and procedures according to  Polish/European 
Society of Cardiology (ESC) standards and to perform 
the QoL assessment. Approval for the study was provided 
by the Bioethics Committee of the Jagiellonian University 
Medical College.
Statistical analysis
Quantitative variables were described with the mean 
± standard deviation (SD) and/or median and/or range 
and/or interquartile range (IQR). Qualitative variables 
were presented as number and/or frequency. Hypotheses 
about the normal distribution of the quantitative variables 
analyzed were verified using the Shapiro–Wilk test. Dif-
ferences in quantitative variables between the 2 groups 
were tested with independent samples using the Student 
t-test or Mann–Whitney U test. An assessment of differ-
ences between qualitative variables was performed using 
the χ2 test or Fisher’s exact test. An analysis of changes 
in quantitative variables, before and after procedure, was 
performed using the Wilcoxon matched-pairs test, while 
qualitative (dichotomous) variables were analyzed with 
McNemar’s test for repeated measures. Relations between 
SF-36 total score and its change and other variables were 
tested using Spearman’s rank test (rs). Selected variables 
associated with a change in SF-36 total score (p < 0.05) 
in univariate statistical analysis, which did not substantially 
correlate (including correlation coefficient ≥0.6) with other 
independent variables, were included into a multiple linear 
regression analysis. The selection of variables which signifi-
cantly influenced the dependent variable, was performed 
using stepwise backward regression. R2 was calculated and 
an assessment of model adequacy using the Fk,n-k-1 test was 
performed, where “k”  is the number of variables in a model 
and “n” is the number of patients in a group. Statistical 
analyses were performed with STATISTICA v. 12 software 
(StatSoft, Tulsa, USA).
Results
Baseline patient characteristics
The study group included 129 patients (70 female), with 
a mean age of 44.5 ±13.4 (19–76) years, scheduled for per-
cutaneous closure of ASD (n = 56) or PFO (n = 73). Patients 
undergoing percutaneous closure of ASD were older and 
were predominantly female when compared to those un-
dergoing closure of PFO (Table 1). There were 10 patients 
with PFO and a history of stroke, while there was no his-
tory of stroke in patients with ASD. None of the patients 
included in the study had significant neurological deficits. 
When compared to patients with PFO, those with ASD 
more commonly suffered from episodes of palpitations 
(37.5% vs 10.9%), dyspnea (32.1% vs 9.6%), arterial hyperten-
sion (30.4% vs 4.1%), and pulmonary hypertension (33.9% 
vs 0%) before the procedure (p < 0.001 for all compari-
sons between the 2 groups, Table 1). These ASD patients 
also more often used calcium channel blockers (CCB), 
β-blockers and angiotensin-converting enzyme inhibitors 
(ACE-I) when compared with the remainder of the pa-
tients in  the study group. On the other hand, patients 
with PFO, when compared with ASD patients, more com-
monly experienced migraine episodes (Table 1). Ventricu-
lar extrasystolic and supraventricular extrasystolic beats 
were more prevalent in the ASD patients when compared 
to the remainder of patients (median (IQR): 2 (1–900 vs 
1 (0–3) ventricular extrasystolic beats/day, p = 0.017 and 
178 (42–540) vs 8 (0–200) supraventricular extrasystolic 
beats/day, p < 0.001). Detailed characteristics of the study 
group are shown in Table 1.
Baseline QoL assessment
There were differences in almost all the SF-36 scores 
between patients with ASD and PFO (Table 1). In both 
groups of patients with ASC, age negatively correlated with 
SF-36 total score (Table 2). Moreover, SF-36 total score 
correlated inversely with New York Heart Association 
(NYHA) class and positively with LVEF in patients with 
ASD (Table 2). We observed correlations between SF-36 
total score after PFO closure and radiation absorbed dose 
(rs = 0.31; p = 0.009) and right ventricular longitudinal 
dimension (rs = 0.25; p = 0.041). Additionally, a correlation 
was seen between SF-36 total score after ASD closure and 
mid-cavity right ventricular linear dimension (rs = 0.29; 
p = 0.034). These correlations, however, were not seen 
in the other groups studied or before the procedure. Left 
ventricular diastolic dimension, left ventricular systolic di-
mension, proximal right ventricular outflow tract (RVOT 
prox), and basal right ventricular linear dimension did not 
correlate with SF-36 total score before or after ASC closure 
in patients with ASD or PFO considered separately. Quality 
of life, reflected by SF-36 total score, in patients with ASD 
was lower than in patients with PFO (Table 1). Patients 
with history of stroke had a tendency towards lower SF-36 
total score than the remaining subjects (95.0 (87–108) vs 
120 (88–132); p = 0.057).
Procedures performed
The  septal occluders were successfully implanted 
in 124 patients. In 5 patients, the procedure was not per-
formed (Table 1). The diameter of the implanted septal 
occluders ranged from 7  mm to  34  mm (median: 25; 
25–28 mm). The ASC occlusion, as reflected by fluoros-
copy time and radiation absorbed dose, appeared more 
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difficult in patients with ASD when compared to patients 
with PFO (fluoroscopy time: 7.4 (4–15) vs 4 (3–6) min, 
p < 0.001; radiation absorbed dose: 29 (18–113) vs 16 (10–
36) mGy, p < 0.001). In 1 (0.8%) case, a transient rhythm 
disorder was observed. There were no serious complica-
tions, no fractures of the device and no device emboliza-
tions. All patients remained well with no complications 
or new symptoms at the 6-month follow-up.
Patient characteristics and 
quality of life after ASC closure
Six months after the procedure, reduc-
tion of episodic palpitations, dyspnea and 
AF, as well as an increase in NYHA class 
were observed, and in these terms ASD 
patients did not significantly differ from 
patients with PFO.
In addition, 6 months after the proce-
dure, higher SF-36 total scores were noted 
in patients with ASD and PFO (Table 3). 
There were differences in  almost all 
the  SF-36 scores between patients with 
ASD and PFO, except for the SF, BP, MH, 
and vitality subscales (Table  4). In  pa-
tients with ASD, significant improve-
ment in the QoL parameters were noted, 
with the  exception of  the  BP subscale 
(p = 0.675). On the other hand, in patients 
with PFO after the procedure, a significant 
improvement in SF-36 QoL parameters was 
observed, except for the SF (p = 0.253) and 
BP subscales (p = 0.166). After percutane-
ous ASC occlusion, the mean improvement 
in QoL was higher in patients with ASD 
when compared to patients with PFO (Ta-
ble 3). Increased change in SF-36 total score 
was associated with presence of arterial hy-
pertension (p = 0.013), episodes of dyspnea 
(p = 0.034), palpitations (p = 0.048), and use 
of CCB (p = 0.001), β-blockers (p = 0.040) 
and ACE-I (p = 0.003), presence of inter-
atrial septal aneurysm (p  =  0.016), and 
myocardial hypertrophy (p = 0.018) before 
the procedure. Importantly, patients with 
AF had a higher improvement in SF-36 to-
tal score (14 (7–22) vs 6 (1–16); p = 0.005). 
Those with AF episode reduction, when 
compared to  the  remainder, were also 
characterized by a higher change in SF-36 
total score (16 (7–320 vs 7 (1–18); p = 0.03). 
We  also observed correlations between 
an increase in change of the SF-36 total 
score (difference between 6 months after 
ASC occlusion and baseline) and baseline 
supraventricular extrasystolic beats (SVEB; 
rs = 0.28; p = 0.002). However, correlations 
were not observed between increase in the change of SF-36 
total score and ventricular extrasystolic beats (VEB; 
rs = 0.03; p = 0.76). Patients with ASD had a higher improve-
ment in SF-36 total score (14 (6–26) vs 5 (1–13); p = 0.003). 
Importantly, increase in the change of SF-36 total score 
correlated with baseline RVOT prox (rs = 0.20; p = 0.03), 
basal right ventricular linear dimension (RVD1) (rs = 0.31; 
p < 0.001), mid-cavity right ventricular linear dimension 
Table 1. Clinical characteristics of patients undergoing closure of atrial septal communication
Variable ASD(n = 56)
PFO
(n = 73) p-value
Age, mean ±SD [years] 49.8 ±13.3 40.5 ±12.0 <0.001
Male sex, n (%) 12 (21.4) 47 (64.4) <0.001
Comorbidities and CVD risk factors, n (%)
Arterial hypertension
Pulmonary hypertension
Hyperlipidemia
Diabetes mellitus
Obesity
Smoking
Anemia
Migraine
Vasovagal syndrome
Stroke/TIA
Atrial fibrillation
17 (30.4)
19 (33.9)
15 (26.8)
4 (7.1)
3 (5.4)
14 (25.0)
0 (0.0)
0 (0.0)
1 (1.8)
4 (7.1)
17 (30.4)
3 (4.1)
0 (0.0)
7 (9.6)
1 (1.4)
2 (2.7)
9 (12.3)
1 (1.4)
11 (15.1)
3 (4.1)
24 (32.9)
8 (11.0)
<0.001
<0.001
0.010
0.166
0.652
0.062
0.999
0.002
0.632
<0.001
0.006
Quality of life assessed using SF-36 questionnaire, at baseline
SF-36 total score
Physical functioning
Limitations due to physical health
Social functioning
Bodily pain
Mental health
Role limitations due to emotional problems
Vitality
General health
99 (68–129)
41 (29–46)
5 (0–10)
5 (4–7)
6 (4–9)
15 (11–18)
5 (0–15)
11 (9–16)
11 (9–15)
124 (96–132)
44 (41–48)
10 (5–20)
6 (5–8)
8 (6–9)
17 (11–19)
15 (5–15)
13 (8–17)
12 (10–15)
<0.001
0.001
<0.001
0.005
0.084
0.348
0.006
0.159
0.079
Echocardiographic parameters, n (%)
Left-to-right shunt
Interatrial septal aneurysm
Enlarged LA
Enlarged RA
Enlarged right ventricle
Myocardial hypertrophy
54 (96.4)
11 (19.6)
35 (62.5)
37 (66.1)
33 (58.9)
9 (16.1)
41 (56.2)
50 (68.5)
14 (19.2)
14 (19.2)
16 (21.9)
4 (5.5)
<0.001
<0.001
<0.001
<0.001
<0.001
0.074
Device, n (%)
Cardia Ultrasept ASD occluder
Cardia Ultrasept PFO occluder
Memopart ASD occluder
No implanted device
4 (7.1)
0 (0.0)
51 (91.1)
1 (1.8)
0 (0.0)
69 (94.5)
0 (0.0)
4 (5.5)
–
Procedure, n (%)
Without complications
Stopped due to complications
Unsuccessful
55 (98.2)
0 (0.0)
1 (1.8)
69 (94.5)
1 (1.4)
3 (4.1)
NS
Medications, n (%)
CCB
Beta-blocker
ACE-I
18 (32.1)
17 (30.4)
17 (30.4)
1 (1.4)
10 (13.7)
5 (6.8)
<0.001
0.021
<0.001
ACE-I – angiotensin-converting enzyme inhibitor; ASD – atrial septal defect; CCB – calcium 
channel blocker; CVD – cardiovascular disease; LA – left atrium; N – number; NS – nonsignificant; 
PFO – patent foramen ovale; RA – right atrium; SD – standard deviation; SF-36 – 36-item SF-36 
questionnaire; TIA – transient ischemic attack. Values are presented as mean ±SD or median 
(interquartile range) or number and percentage.
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(RVD2) (rs = 0.35; p < 0.001), longitudinal right ventricu-
lar dimension (RVD3) (rs = 0.38; p < 0.001), and TAPSE 
(rs = 0.42; p < 0.001), but not LVEF (rs = −0.005; p = 0.95). 
Additionally, correlations between increase in the change 
of SF-36 total score and baseline left and right atrial area 
were observed (rs = 0.21; p = 0.02 and rs = 0.30; p < 0.001, re-
spectively). We also observed correlations between increase 
in the change of SF-36 total score and decrease in SVEB 
(rs = 0.19; p = 0.04), but not VEB (rs = −0.05; p = 0.55).
Change in SF-36 total score in patients with ASD was 
predicted by TAPSE and RVD3, while in patients with PFO 
this was predicted by TAPSE, lack of arterial hypertension 
and ACE-I use (Table 5).
Discussion
In patients with ASD, the most commonly reported 
symptoms are exertional dyspnea, limitation of physical 
condition and paroxysmal palpitations. Among the causes 
of gradual deterioration of clinical status of patients with 
ASD are age-dependent decline in  left ventricular dia-
stolic compliance, which increases left-to-right shunt, 
the development of pulmonary hypertension, and the ap-
pearance of AF (30.4% of our patients with ASD), which 
often initiates right ventricular heart failure.3 On the other 
hand, the presence of PFO is associated with an increased 
risk of crossed (paradoxical) embolism, which may cause 
a cryptogenic stroke.1,2 In our study, stroke/TIA occurred 
in 32.9% of patients with PFO.
Table 2. Spearman’s correlations (rs) between quantitative variables and SF-36 total score at baseline and after closure of atrial septal communication
Variable
SF-36 total score before ASC closure 
rs (p-value)
SF-36 total score after ASC closure 
rs (p-value)
ASC ASD PFO ASC ASD PFO
Age [years] –0.34 (<0.001) –0.28 (0.038) –0.32 (0.005) –0.32 (<0.001) –0.34 (0.010) –0.28 (0.022) 
NYHA class –0.31 (<0.001) –0.29 (0.030) –0.19 (0.113) –0.32 (<0.001) –0.37 (0.006) –0.13 (0.302)
Echocardiography
LVEF [%] 0.22 (0.014) 0.59 (<0.001) –0.01 (0.944) 0.37 (<0.001) 0.71 (<0.001) 0.21 (0.090) 
TAPSE [mm] –0.29 (0.001) –0.38 (0.004) –0.10 (0.342) –0.04 (0.662) –0.18 (0.189) 0.21 (0.077)
LA area [cm2] –0.20 (0.025) –0.29 (0.029) 0.09 (0.426) –0.13 (0.165) –0.26 (0.053) 0.17 (0.168)
RA area [cm2] –0.21 (0.016) –0.29 (0.030) 0.04 (0.752) –0.10 (0.257) –0.19 (0.173) 0.13 (0.296)
Qp/Qs ratio –0.33 (<0.001) –0.23 (0.094) * –0.34 (<0.001) –0.19 (0.161) *
Procedure
Fluoroscopy time [min] –0.31 (<0.001) –0.31 (0.022) –0.04 (0.711) –0.30 (0.001) –0.35 (0.009) 0.10 (0.402)
ASD – atrial septal defect; ASC – atrial septal communication; LVEF – left ventricular ejection fraction; NYHA – New York Heart Association; PFO – patent 
foramen ovale; RA – right atrium; TAPSE – tricuspid annular plane systolic excursion; LA – left atrium; Qp/Qs ratio – pulmonary to systemic blood flow ratio; 
SF-36 – 36-item SF-36 questionnaire. *Qp/Qs ratio = 1 in all patients.
Table 3. Changes in SF-36 total score before and 6 months after successful closure of atrial septal communication
Variable
SF-36 total score
ASC
before
(n = 124)
ASC  
6-m FU
ASD
before
(n = 55)
ASD  
6-m FU
PFO
before
(n = 69)
PFO  
6-m FU
Median 111 121 98 117 120 131
Interquartile range 87.5–131.0 102.5–139.0 56–129 82–136 96–132 121–140
p-value <0.001* <0.001* <0.001*
6-m FU – 6-month follow-up; ASD – atrial septal defect; ASC – atrial septal communication; PFO – patent foramen ovale; SF-36 – 36-item 
SF-36 questionnaire. Values are presented as median (interquartile range). *p-value for comparison of patients before and after the procedure.
Table 4. Comparison of quality of life assessed with SF-36 between 
patients after atrial septal communication occlusion (ASD, PFO)
Variable ASD
*
(n = 55)
PFO*
(n = 69) p-value
SF-36 total score 117 (82–136) 131 (121–140) <0.001
Physical functioning 40 (31–44) 48 (44–48) <0.001
Limitations due 
to physical health
10 (0–15) 15 (8–20) 0.005
Social functioning 6 (5–8) 6 (5–8) 0.844
Bodily pain 8 (5–8) 8 (6–9) 0.215
Mental health 17 (12–21) 17 (12–21) 0.957
Role limitations due 
to emotional problems
15 (5–15) 15 (15–15) 0.009
Vitality 13 (9–16) 16 (9–17) 0.092
General health 13 (9–15) 14 (12–17) 0.011
ASD – atrial septal defect; PFO – patent foramen ovale; SF-36 – a 36-item 
SF-36 questionnaire. Values are presented as median (interquartile range). 
*In 5 patients the procedure was not performed (in 4 patients with PFO 
and in 1 patient with ASD).
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The  results of  percutaneous ASC closure are very 
promising,13 but the procedure is not free of potential 
complications.20–22 Percutaneous occlusion does not lead 
to postoperative scarring on the chest, which is a signifi-
cant advantage from the patient’s perspective. This may 
have a major impact on the QoL, especially that of young 
women.11 The assessment of health status after correction 
of the ASC is based primarily on the results of echocar-
diographic, radiological and laboratory studies.7 However, 
they do not always reflect a satisfactory level of QoL. In this 
study, it was shown that the QoL between patients before 
percutaneous occlusion of ASD and PFO differs. Special 
attention is drawn to a subjectively low grade in the as-
sessment of RP (limitations in performing roles and/or 
in work ability), SF (social life, meetings with family) and 
RE (anxiety, bad mood, lack of work) subscales, but not 
the MH (nervousness, depression, unhappiness, and sad-
ness) and VT (willingness to live, tiredness, lack of en-
ergy) subscales. On the other hand, in the self-assessment 
reflecting GH, a trend towards lower QoL was observed 
in patients with ASD. After ASC occlusion, QoL in all sub-
scales improved, except for sense of pain. Deterioration 
of patient functioning (performing roles) due to physical 
health (limitation in work ability) at the 6-month follow-
up after ASD occlusion may result from restrictions rec-
ommended by doctors and suggestions by the patient’s 
family members before the procedure. Such situations 
are very common and unfortunately are also transferred 
to the post-procedural period.11,12 Asymptomatic patients 
or those with mild symptoms (a majority of patients with 
PFO) may not experience such a significant improvement 
after the procedure when compared to patients with ASD, 
in whom effective occlusion of the defect is associated with 
resolution of significant ailments. Quality of life between 
patients with ASD and PFO before the procedure did not 
differ in the subscales of BP, MH, VT, and GH. The ex-
istence of comorbidities, such as arterial hypertension, 
episodes of AF, dyspnea and palpitations, as well as the use 
of medications (CCB, β-blockers, and ACE-I), influences 
QoL. Significant associations of change in SF-36 total score 
with a reduction of the abovementioned symptoms after 
ASC occlusion were noted. Patients after ASD and PFO 
occlusion did not differ in regard to SF, BP, MH, and VT. 
Similarly, after percutaneous ASD closure, Komar et al.4 
observed a significant improvement in the clinical condi-
tion of patients and reduction in the frequency of dys-
pnea, palpitations and resolution of right heart volume 
overload. This was reflected by a decrease in right atrial 
area and right ventricular size (diastolic and systolic di-
mension as well as right ventricular area) and a significant 
improvement in QoL. On the other hand, Siudalska et al.11 
observed decreased overall QoL and physical health in pa-
tients after surgical correction of ASD than in the control 
group. At the same time, there were no differences in men-
tal health between the groups. The only category signifi-
cantly differentiating the compared groups was social 
functioning, which was worse in patients who had under-
gone surgical correction of ASD. Somatic disorders were 
significantly more common in surgical patients. In our 
study, we have shown that the procedure-related change 
in self-assessed QoL by patients was associated with right 
ventricular and atrial dimensions. In patients with ASD, 
change in SF-36 total score was predicted by TAPSE and 
RVD3, while in patients with PFO, this change was pre-
dicted by TAPSE, lack of arterial hypertension and ACE-I 
use. Therefore, in both groups, patients with better right 
ventricular function (TAPSE) before percutaneous closure 
of ASC may benefit the most, in terms of QoL improve-
ment, from ASC occlusion. In patients with ASD, increased 
longitudinal right ventricular dimension plays an impor-
tant role, while in patients with PFO, lack of arterial hy-
pertension and ACE-I use are important factors. These 
observations are in line with previous studies in different 
groups of patients.23,24
Our study has several limitations, including the observa-
tional character of the study, a relatively short follow-up and 
Table 5. Multiple regression analysis of predictors of change in SF-36 total score (difference between 6 months after atrial septal communication occlusion 
and baseline), which reflects general increase in SF-36 total score
Multiple regression 
analysis Variables
Standardized 
coefficients β
Unstandardized  
coefficients Β
95% CI for B
p-value
lower upper
ASC (R2 = 0.35;  
F4,119 = 15.99; p < 0.001)
TAPSE [mm] 0.40 3.14 1.93 4.35 <0.001
RVD3 [mm] 0.26 0.63 0.26 1.00 0.001
arterial hypertension –0.38 –10.18 –20.00 –0.38 0.042
ACE-I 0.42 10.54 1.28 19.79 0.026
ASD (R2 = 0.38;
F = 2,52 = 15.8; p < 0.001)
TAPSE [mm] 0.38 2.76 1.04 4.48 0.002
RVD3 [mm] 0.36 1.05 0.37 1.73 0.003
PFO (R2 = 0.30;  
F3,65 = 9.48; p < 0.001)
TAPSE [mm] 0.38 3.41 1.51 5.30 0.001
arterial hypertension –0.34 –16.38 –28.12 –3.64 0.013
ACE-I 0.44 13.90 5.59 22.2 0.001
95% CI – 95% confidence interval; ACE-I – angiotensin-converting enzyme inhibitor; ASD – atrial septal defect; NS – not significant; PFO – patent foramen 
ovale; SF-36 – 36-item SF-36 questionnaire; RVD3 – longitudinal right ventricular dimension; TAPSE – tricuspid annular plane systolic excursion.
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a small group of patients investigated. However, the changes 
described are significant. On the other hand, longer Holter 
ECG monitoring could increase detection and provide more 
detailed characteristics of arrhythmias.
Conclusions
Patients with atrial septal defect have a lower QoL than 
patients with patent foramen ovale, both before and af-
ter percutaneous ASC occlusion. Improvement of quality 
of life in patients with atrial septal defect is higher than 
in those with patent foramen ovale. The change in self-
assessed QoL after the procedure was associated with 
episodic arrhythmia and predicted by echocardiographic 
and clinical parameters. Patient education on potential 
role limitations should be considered in patients with ASC, 
especially those with ASD.
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